IN THE UNITED STATES PATENT AND TRADEMARK OFFICE RECEIVED GENTRAL FAX CENTER

Applicants:	David A. Cheresh et al.)	SEP 2 2 2003
Application No.	09/701,500)	
Filed:	November 29, 2000)) Group Art Unit: 1635	OFFICIAL
For:	METHODS AND COMPOSITIONS USEFUL FOR MODULATION OF ANGIOGENESIS USING TYROSINE KINASE SRC)))	
Examiner:	Richard A. Schnizer) Attorney Docket No. <u>TSRI 651.1</u>	

RESPONSE TO RESTRICTION REQUIREMENT

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

In response to the Office Action dated 18 August 2003 on the above-identified application, applicants hereby provisionally elect for prosecution at this time the claims of Group III, i.e., claims 1-4, 12-16, 33 and 34 drawn to compositions comprising a nucleotide sequence capable of expressing an active Src protein. This election is made without traverse.

An early action on the merits is solicited.

Respectfully submitted,

September 18, 2003

Talivaldis Cepuritis (Reg. No. 20,818)

OLSON & HIERL, LTD. 20 North Wacker Drive, 36th Floor Chicago, Illinois 60606 (312) 580-1180

CERTIFICATE OF FACSIMILE TRANSMISSION

I hereby certify that this paper is being transmitted by facsimile transmission to Examiner Richard Schnizer via Fax No. 703-872-9306 on September 18, 2003.

Talivaldis Cepuritis (Reg. No. 20,818)